---
annotation-target: s00281-022-00962-4.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-29T00:47:14.526Z","updated":"2022-09-29T00:47:14.526Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":500,"end":1330},{"type":"TextQuoteSelector","exact":" One class of cellular therapies—chimeric antigen receptor (CAR)-modified T cells—has achieved impressive results in distinct blood cancer indications. These existing cellular therapies treating blood cancers face significant relapse rates, and their application beyond hematology has been underwhelming, especially in solid oncology. Major reasons for resist-ance source largely in the tumor microenvironment (TME). The TME in fact functionally suppresses, restricts, and excludes adoptive immune cells, which limits the efficacy of cellular immunotherapies from the onset. Many promising efforts are ongoing to adapt cellular immunotherapies to address these obstacles, with the aim of reshaping the tumor microenvironment to ameliorate function and to achieve superior efficacy against both hematological and solid malignancies","prefix":"cations is steadily increas-ing.","suffix":".Keywords  Cellular immunotherap"}]}]}
>```
>%%
>*%%PREFIX%%cations is steadily increas-ing.%%HIGHLIGHT%% ==One class of cellular therapies—chimeric antigen receptor (CAR)-modified T cells—has achieved impressive results in distinct blood cancer indications. These existing cellular therapies treating blood cancers face significant relapse rates, and their application beyond hematology has been underwhelming, especially in solid oncology. Major reasons for resist-ance source largely in the tumor microenvironment (TME). The TME in fact functionally suppresses, restricts, and excludes adoptive immune cells, which limits the efficacy of cellular immunotherapies from the onset. Many promising efforts are ongoing to adapt cellular immunotherapies to address these obstacles, with the aim of reshaping the tumor microenvironment to ameliorate function and to achieve superior efficacy against both hematological and solid malignancies== %%POSTFIX%%.Keywords  Cellular immunotherap*
>%%LINK%%[[#^5p23nwersb4|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5p23nwersb4


>%%
>```annotation-json
>{"created":"2022-09-29T00:47:32.085Z","updated":"2022-09-29T00:47:32.085Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":1889,"end":2039},{"type":"TextQuoteSelector","exact":"verall, cellular immunotherapies have so far employed dendritic cell (DC), T cells, or natural killer cells (NK) into patients for treatment of diseas","prefix":" potential of these approaches.O","suffix":"e. DC vaccines, which uti-lize m"}]}]}
>```
>%%
>*%%PREFIX%%potential of these approaches.O%%HIGHLIGHT%% ==verall, cellular immunotherapies have so far employed dendritic cell (DC), T cells, or natural killer cells (NK) into patients for treatment of diseas== %%POSTFIX%%e. DC vaccines, which uti-lize m*
>%%LINK%%[[#^rhfcu63zp1m|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^rhfcu63zp1m


>%%
>```annotation-json
>{"created":"2022-09-29T00:48:17.336Z","updated":"2022-09-29T00:48:17.336Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":2499,"end":2966},{"type":"TextQuoteSelector","exact":"Various DC vaccines have shown promis-ing safety and efficacy in clinical trials against pediatric solid tumors and other forms of solid tumors [1–3]. These efforts in developing DC vaccine approaches culminated in FDA approval of Sipuleucel-T, a DC vaccine for the treatment of prostate cancer [4]. While Sipuleucel T did improve survival in prostate cancer patients, adoption of this therapy in clinics has been limited over questions of clinical efficacy and cost ","prefix":"unt a specific immune response. ","suffix":"[5]. In fact, marketing authoriz"}]}]}
>```
>%%
>*%%PREFIX%%unt a specific immune response.%%HIGHLIGHT%% ==Various DC vaccines have shown promis-ing safety and efficacy in clinical trials against pediatric solid tumors and other forms of solid tumors [1–3]. These efforts in developing DC vaccine approaches culminated in FDA approval of Sipuleucel-T, a DC vaccine for the treatment of prostate cancer [4]. While Sipuleucel T did improve survival in prostate cancer patients, adoption of this therapy in clinics has been limited over questions of clinical efficacy and cost== %%POSTFIX%%[5]. In fact, marketing authoriz*
>%%LINK%%[[#^x3g62ypc5ck|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^x3g62ypc5ck


>%%
>```annotation-json
>{"created":"2022-09-29T00:48:46.955Z","updated":"2022-09-29T00:48:46.955Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":3046,"end":3440},{"type":"TextQuoteSelector","exact":"While NK cell therapy to date has remained investigational only, most efforts and advances in cellular therapy have revolved around T cell-based therapeu-tics. These therapies can be subclassified into tumor infiltrat-ing lymphocytes (TIL), chimeric antigen receptor (CAR)-T cells, and recombinant T cell receptor (TCR)-T cells. TILs are  heterogeneous  populations  of  immune  cells,  mostly ","prefix":"ithdrawn in the European Union. ","suffix":" This article is a contribution "}]}]}
>```
>%%
>*%%PREFIX%%ithdrawn in the European Union.%%HIGHLIGHT%% ==While NK cell therapy to date has remained investigational only, most efforts and advances in cellular therapy have revolved around T cell-based therapeu-tics. These therapies can be subclassified into tumor infiltrat-ing lymphocytes (TIL), chimeric antigen receptor (CAR)-T cells, and recombinant T cell receptor (TCR)-T cells. TILs are  heterogeneous  populations  of  immune  cells,  mostly== %%POSTFIX%%This article is a contribution*
>%%LINK%%[[#^762v5594bd4|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^762v5594bd4


>%%
>```annotation-json
>{"created":"2022-09-29T00:49:18.545Z","updated":"2022-09-29T00:49:18.545Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":4169,"end":4890},{"type":"TextQuoteSelector","exact":"omposed  of  T  cells,  that  are  extracted  from  a  patient’s  own cancer as they are presumed to have high specificity against those tumors [6]. After expansion, the cells are rein-troduced into the patient in a therapeutic intention. Such treatment was initially sought for in melanoma treatment, where high remission rates were observed [7]. The burden of generation and high variability of the product made up for an uneven comparison to checkpoint blockade and dis-missed TIL therapy for a while. Recently, autologous TIL treatment after immune checkpoint blockade (ICB) failure demonstrated robust remission rates in a significant share of melanoma patients, bringing the concept back to clinical investigations ","prefix":" Seminars in Immunopathology1 3c","suffix":"[7].Meanwhile, TCRs and CARs are"}]}]}
>```
>%%
>*%%PREFIX%%Seminars in Immunopathology1 3c%%HIGHLIGHT%% ==omposed  of  T  cells,  that  are  extracted  from  a  patient’s  own cancer as they are presumed to have high specificity against those tumors [6]. After expansion, the cells are rein-troduced into the patient in a therapeutic intention. Such treatment was initially sought for in melanoma treatment, where high remission rates were observed [7]. The burden of generation and high variability of the product made up for an uneven comparison to checkpoint blockade and dis-missed TIL therapy for a while. Recently, autologous TIL treatment after immune checkpoint blockade (ICB) failure demonstrated robust remission rates in a significant share of melanoma patients, bringing the concept back to clinical investigations== %%POSTFIX%%[7].Meanwhile, TCRs and CARs are*
>%%LINK%%[[#^uq5rwphgazp|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^uq5rwphgazp


>%%
>```annotation-json
>{"created":"2022-09-29T00:49:47.797Z","updated":"2022-09-29T00:49:47.797Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":4895,"end":5569},{"type":"TextQuoteSelector","exact":"eanwhile, TCRs and CARs are receptors genetically engineered into T cells isolated from patient blood and rein-troduced into the patient to target cancers. TCRs used are derived from natural sequences that bind the desired antigen and behave similarly to normal TCRs [8]. In contrast, CARs are fully synthetic receptors not naturally found and con-sist of an antibody-derived single chain variable fragment (scFv) combined with intracellular T cell receptor signaling domains only (so called 1st generation CAR) or with one or more intracellular domains of costimulatory molecules to further activate the T cell when antigen is bound (so called 2nd and 3rd generation CAR) [","prefix":"to clinical investigations [7].M","suffix":"9]. The major difference is HLA "}]}]}
>```
>%%
>*%%PREFIX%%to clinical investigations [7].M%%HIGHLIGHT%% ==eanwhile, TCRs and CARs are receptors genetically engineered into T cells isolated from patient blood and rein-troduced into the patient to target cancers. TCRs used are derived from natural sequences that bind the desired antigen and behave similarly to normal TCRs [8]. In contrast, CARs are fully synthetic receptors not naturally found and con-sist of an antibody-derived single chain variable fragment (scFv) combined with intracellular T cell receptor signaling domains only (so called 1st generation CAR) or with one or more intracellular domains of costimulatory molecules to further activate the T cell when antigen is bound (so called 2nd and 3rd generation CAR) [== %%POSTFIX%%9]. The major difference is HLA*
>%%LINK%%[[#^4xt89s2njy|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^4xt89s2njy


>%%
>```annotation-json
>{"created":"2022-09-29T00:51:09.850Z","updated":"2022-09-29T00:51:09.850Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":6587,"end":7113},{"type":"TextQuoteSelector","exact":"In hematological malignancies, CAR-T cells have achieved unparalleled clini-cal results as treatment for relapsed and refractory patients with otherwise poor prognosis [15]. Despite successes and high response rates, patients undergoing CAR-T cell therapy often experience relapse after only weeks or months, dem-onstrating that current forms of therapy must be improved [16]. At the same time, CAR-T cell therapies in their current form have shown modest or negligible efficacy in clinical trials for a range of solid tumors ","prefix":"ersistence phenotypes [13, 14]. ","suffix":"[17, 18]. Overall, ongo-ing  iss"}]}]}
>```
>%%
>*%%PREFIX%%ersistence phenotypes [13, 14].%%HIGHLIGHT%% ==In hematological malignancies, CAR-T cells have achieved unparalleled clini-cal results as treatment for relapsed and refractory patients with otherwise poor prognosis [15]. Despite successes and high response rates, patients undergoing CAR-T cell therapy often experience relapse after only weeks or months, dem-onstrating that current forms of therapy must be improved [16]. At the same time, CAR-T cell therapies in their current form have shown modest or negligible efficacy in clinical trials for a range of solid tumors== %%POSTFIX%%[17, 18]. Overall, ongo-ing  iss*
>%%LINK%%[[#^pohw842u5c8|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^pohw842u5c8


>%%
>```annotation-json
>{"created":"2022-09-29T00:51:24.418Z","updated":"2022-09-29T00:51:24.418Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":7281,"end":7417},{"type":"TextQuoteSelector","exact":"antigen loss, low levels of immune cell infiltration, and the effects of an intensely immunosuppres-sive tumor microenvironment (TME) [1","prefix":"d back to a few main obstacles: ","suffix":"7, 18]. As several of these aspe"}]}]}
>```
>%%
>*%%PREFIX%%d back to a few main obstacles:%%HIGHLIGHT%% ==antigen loss, low levels of immune cell infiltration, and the effects of an intensely immunosuppres-sive tumor microenvironment (TME) [1== %%POSTFIX%%7, 18]. As several of these aspe*
>%%LINK%%[[#^abjvvq33ohi|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^abjvvq33ohi


>%%
>```annotation-json
>{"created":"2022-09-29T00:52:12.388Z","updated":"2022-09-29T00:52:12.388Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":8035,"end":8858},{"type":"TextQuoteSelector","exact":". The TME can support the sur-vival and proliferation of tumor cells and tumor-associated cell populations and thus contributes a major share to cancer hallmarks (Fig. 1). Crucially, the TME suppresses the ability of cellular therapies to normally function through induction of inhibitory signals as well as forming physical barriers preventing contact with tumor cells in both solid tumors and hematological malignancies [20]. These immunosup-pressive aspects relevant to cellular therapies are the focus of this section. Suppressive mechanisms embedded in the TME can be subdivided into chemokine-induced migration of immunosuppressive cells, cytokine-mediated suppres-sion,  membrane-bound  and  contact  suppression,  cancer-associated fibroblast-mediated factors, stromal restriction, and aberrant vasculature (Fig. 1)","prefix":"od vessels, and secreted factors","suffix":".Chemokines released by tumor ce"}]}]}
>```
>%%
>*%%PREFIX%%od vessels, and secreted factors%%HIGHLIGHT%% ==. The TME can support the sur-vival and proliferation of tumor cells and tumor-associated cell populations and thus contributes a major share to cancer hallmarks (Fig. 1). Crucially, the TME suppresses the ability of cellular therapies to normally function through induction of inhibitory signals as well as forming physical barriers preventing contact with tumor cells in both solid tumors and hematological malignancies [20]. These immunosup-pressive aspects relevant to cellular therapies are the focus of this section. Suppressive mechanisms embedded in the TME can be subdivided into chemokine-induced migration of immunosuppressive cells, cytokine-mediated suppres-sion,  membrane-bound  and  contact  suppression,  cancer-associated fibroblast-mediated factors, stromal restriction, and aberrant vasculature (Fig. 1)== %%POSTFIX%%.Chemokines released by tumor ce*
>%%LINK%%[[#^j98i0kosj7s|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^j98i0kosj7s


>%%
>```annotation-json
>{"created":"2022-09-29T00:52:46.149Z","updated":"2022-09-29T00:52:46.149Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":9002,"end":9593},{"type":"TextQuoteSelector","exact":"-regulatory cells (T-reg) are recruited by tumor-secreted chemokines C–C motif ligand (CCL)5,  CCL17,  and  CCL22  [21].  Chemokines  such  as  CCL2, CCL5, and C-X-C motif chemokine (CXCL)5 recruit myeloid-derived suppressor cells (MDSC) [22], a heterog-enous though poorly defined population of myeloid cells that are most clearly related by their myeloid lineage and suppressive capacity [22]. Tumor-associated macrophages (TAM), a suppressive type of macrophage closely related to M2 macrophages, derive from tumor-associated mono-cytes that migrate to tumors via CCL2 and CCL3 gradients ","prefix":"or microenvironment (Fig. 1A). T","suffix":"[23]. Other varieties of recruit"}]}]}
>```
>%%
>*%%PREFIX%%or microenvironment (Fig. 1A). T%%HIGHLIGHT%% ==-regulatory cells (T-reg) are recruited by tumor-secreted chemokines C–C motif ligand (CCL)5,  CCL17,  and  CCL22  [21].  Chemokines  such  as  CCL2, CCL5, and C-X-C motif chemokine (CXCL)5 recruit myeloid-derived suppressor cells (MDSC) [22], a heterog-enous though poorly defined population of myeloid cells that are most clearly related by their myeloid lineage and suppressive capacity [22]. Tumor-associated macrophages (TAM), a suppressive type of macrophage closely related to M2 macrophages, derive from tumor-associated mono-cytes that migrate to tumors via CCL2 and CCL3 gradients== %%POSTFIX%%[23]. Other varieties of recruit*
>%%LINK%%[[#^sbsev11f4rq|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^sbsev11f4rq


>%%
>```annotation-json
>{"created":"2022-09-29T00:53:03.872Z","updated":"2022-09-29T00:53:03.872Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":9716,"end":9851},{"type":"TextQuoteSelector","exact":"while  cells  such  as  bone-marrow-derived  mesenchymal  stem cells (MSC) additionally contribute to the develop-ment of the TME [26].","prefix":"ute  to  suppression  [24,  25] ","suffix":" Tumor cells and recruited immu-"}]}]}
>```
>%%
>*%%PREFIX%%ute  to  suppression  [24,  25]%%HIGHLIGHT%% ==while  cells  such  as  bone-marrow-derived  mesenchymal  stem cells (MSC) additionally contribute to the develop-ment of the TME [26].== %%POSTFIX%%Tumor cells and recruited immu-*
>%%LINK%%[[#^fiad3p0p234|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^fiad3p0p234


>%%
>```annotation-json
>{"created":"2022-09-29T00:53:55.427Z","updated":"2022-09-29T00:53:55.427Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":10188,"end":11035},{"type":"TextQuoteSelector","exact":"In addition to these soluble factors, tumors, MDSCs, TAMs, and T-regs directly suppress immune function by upregulating inhibitory signal-ing molecules on their membrane, including the well-known checkpoint  molecules  programmed  cell  death  protein  1  (PD-1)  and  cytotoxic  T-lymphocyte-associated  protein  4  (CTLA-4), among others [20, 27] (Fig. 1C). Tumor cells furthermore  prominently  express  “don’t  eat  me”  signals  such as CD47 and CD24 to escape immunosurveillance by the innate immune system[28–30], and intratumoral T-regs can  mediate  antigen-dependent  and  -independent  inhibi-tion of immune cells [21]. Another intratumoral cell type, cancer-associated fibroblasts (CAF), are a highly heteroge-neous population of activated fibroblasts that form around tumors and further shape the tumor microenvironment [31] (Fig. 1D)","prefix":"ed immune cells [20] (Fig. 1B). ","suffix":". Though the mechanisms of CAF d"}]}]}
>```
>%%
>*%%PREFIX%%ed immune cells [20] (Fig. 1B).%%HIGHLIGHT%% ==In addition to these soluble factors, tumors, MDSCs, TAMs, and T-regs directly suppress immune function by upregulating inhibitory signal-ing molecules on their membrane, including the well-known checkpoint  molecules  programmed  cell  death  protein  1  (PD-1)  and  cytotoxic  T-lymphocyte-associated  protein  4  (CTLA-4), among others [20, 27] (Fig. 1C). Tumor cells furthermore  prominently  express  “don’t  eat  me”  signals  such as CD47 and CD24 to escape immunosurveillance by the innate immune system[28–30], and intratumoral T-regs can  mediate  antigen-dependent  and  -independent  inhibi-tion of immune cells [21]. Another intratumoral cell type, cancer-associated fibroblasts (CAF), are a highly heteroge-neous population of activated fibroblasts that form around tumors and further shape the tumor microenvironment [31] (Fig. 1D)== %%POSTFIX%%. Though the mechanisms of CAF d*
>%%LINK%%[[#^crald0kl5f6|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^crald0kl5f6


>%%
>```annotation-json
>{"created":"2022-09-29T00:54:34.850Z","updated":"2022-09-29T00:54:34.850Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":14376,"end":14613},{"type":"TextQuoteSelector","exact":"For instance, application via intra-tumoral  injection  leads  to  increased  efficacy  of  adoptive  CAR-T cells in certain tumor indications by physically cir-cumventing the issue of TME exclusion and adoptive cell infiltration [42, 43","prefix":"ing  existing cellular therapy. ","suffix":"]. To further address the issues"}]}]}
>```
>%%
>*%%PREFIX%%ing  existing cellular therapy.%%HIGHLIGHT%% ==For instance, application via intra-tumoral  injection  leads  to  increased  efficacy  of  adoptive  CAR-T cells in certain tumor indications by physically cir-cumventing the issue of TME exclusion and adoptive cell infiltration [42, 43== %%POSTFIX%%]. To further address the issues*
>%%LINK%%[[#^yucthamcvk|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^yucthamcvk


>%%
>```annotation-json
>{"created":"2022-09-29T00:55:14.455Z","updated":"2022-09-29T00:55:14.455Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":18911,"end":19183},{"type":"TextQuoteSelector","exact":"cov-ering topics such as increasing intratumoral immune cell infiltration, changing the cytokine environment within the tumor, elimination of suppressive immune cell populations, removal of physical barriers presented by the stroma, and targeting of the tumor vasculature ","prefix":"obstacles presented by the TME, ","suffix":"(Fig. 2). Additionally, we focus"}]}]}
>```
>%%
>*%%PREFIX%%obstacles presented by the TME,%%HIGHLIGHT%% ==cov-ering topics such as increasing intratumoral immune cell infiltration, changing the cytokine environment within the tumor, elimination of suppressive immune cell populations, removal of physical barriers presented by the stroma, and targeting of the tumor vasculature== %%POSTFIX%%(Fig. 2). Additionally, we focus*
>%%LINK%%[[#^h34lbdaw84f|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^h34lbdaw84f


>%%
>```annotation-json
>{"created":"2022-09-29T00:56:18.407Z","updated":"2022-09-29T00:56:18.407Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":28963,"end":29358},{"type":"TextQuoteSelector","exact":"For example, CAR-T cells against CD123, tar-get  both  Hodgkin  lymphoma  (HL)  cells  as  well  as  TAM  that prominently present in the tumor microenvironment of that indication, as similar expression is found on both cell populations [84]. These CAR-T cells recognize and kill both HL cells and TAMs, which leads to resistance against sup-pression, and sustained clearance in in vivo models [","prefix":"ion  or  remodeling  (Fig. 2C). ","suffix":"84]. Targeting of CD123 thus adv"}]}]}
>```
>%%
>*%%PREFIX%%ion  or  remodeling  (Fig. 2C).%%HIGHLIGHT%% ==For example, CAR-T cells against CD123, tar-get  both  Hodgkin  lymphoma  (HL)  cells  as  well  as  TAM  that prominently present in the tumor microenvironment of that indication, as similar expression is found on both cell populations [84]. These CAR-T cells recognize and kill both HL cells and TAMs, which leads to resistance against sup-pression, and sustained clearance in in vivo models [== %%POSTFIX%%84]. Targeting of CD123 thus adv*
>%%LINK%%[[#^kstztaubli9|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^kstztaubli9


>%%
>```annotation-json
>{"created":"2022-09-29T00:57:27.841Z","updated":"2022-09-29T00:57:27.841Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":32687,"end":33049},{"type":"TextQuoteSelector","exact":" Though the anti-tumor function of these CAR-NK cells was promising, no conclusive result on increased safety and reduced toxicity was determined. Ulti-mately, targeting intratumoral suppressive cells has shown to be an efficacious approach, though special care needs to be taken to achieve effective targeting without inducing harmful off-tumor adverse effects.","prefix":"AR-T cell-induced toxicity [89].","suffix":"Removing physical barriers to ce"}]}]}
>```
>%%
>*%%PREFIX%%AR-T cell-induced toxicity [89].%%HIGHLIGHT%% ==Though the anti-tumor function of these CAR-NK cells was promising, no conclusive result on increased safety and reduced toxicity was determined. Ulti-mately, targeting intratumoral suppressive cells has shown to be an efficacious approach, though special care needs to be taken to achieve effective targeting without inducing harmful off-tumor adverse effects.== %%POSTFIX%%Removing physical barriers to ce*
>%%LINK%%[[#^6jwpl6blul8|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^6jwpl6blul8


>%%
>```annotation-json
>{"created":"2022-09-29T00:58:06.402Z","updated":"2022-09-29T00:58:06.402Z","document":{"title":"Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","link":[{"href":"urn:x-pdf:8cb69d0b10b79841a074dbffd5353d8b"},{"href":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf"}],"documentFingerprint":"8cb69d0b10b79841a074dbffd5353d8b"},"uri":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","target":[{"source":"vault:/hematology-theroy/papers/Heidelberg-pancancer/s00281-022-00962-4.pdf","selector":[{"type":"TextPositionSelector","start":33606,"end":34217},{"type":"TextQuoteSelector","exact":"Fibroblast activation protein (FAP), a transmembrane serine protease/type 2 dipeptidyl peptidase, has been shown to be one of the preponderantly expressed surface markers of most CAF populations and cor-relates with poor clinical outcome in various carcinomas [90, 91]. With this rationale, anti-FAP CAR-T cells were developed to target CAFs, with multiple concepts aiming to treat malignant pleural mesothelioma (MPM) in human and murine models [92, 93]. These efforts advanced into a now-completed phase I clinical trial against MPM, demonstrating good safety data and encouraging efficacy (NCT01722149) [94].","prefix":"o-nents are digested (Fig. 2D). ","suffix":" Similarly, pre-clinical studies"}]}]}
>```
>%%
>*%%PREFIX%%o-nents are digested (Fig. 2D).%%HIGHLIGHT%% ==Fibroblast activation protein (FAP), a transmembrane serine protease/type 2 dipeptidyl peptidase, has been shown to be one of the preponderantly expressed surface markers of most CAF populations and cor-relates with poor clinical outcome in various carcinomas [90, 91]. With this rationale, anti-FAP CAR-T cells were developed to target CAFs, with multiple concepts aiming to treat malignant pleural mesothelioma (MPM) in human and murine models [92, 93]. These efforts advanced into a now-completed phase I clinical trial against MPM, demonstrating good safety data and encouraging efficacy (NCT01722149) [94].== %%POSTFIX%%Similarly, pre-clinical studies*
>%%LINK%%[[#^agqco838lq|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^agqco838lq
